Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 6Other hematologic neoplasm 4Tumor-Agnostic 3Gynecologic 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 3Neoplasms, Second Primary 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Antineoplastic Agents × Tumor-Agnostic × Clear all
NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT04696250 2021-01-06

AVATAR

University Hospital, Caen

Unknown
5,000,000 enrolled
Tumor-Agnostic

Neoplasms

NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡